{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:15:00Z","timestamp":1761862500781},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.lungcan.2005.09.002","type":"journal-article","created":{"date-parts":[[2005,11,15]],"date-time":"2005-11-15T12:14:43Z","timestamp":1132056883000},"page":"89-96","source":"Crossref","is-referenced-by-count":46,"title":["Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer"],"prefix":"10.1016","volume":"51","author":[{"given":"Arkadiusz Z.","family":"Dudek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof Lesniewski-","family":"Kmak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Koopmeiners","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mani","family":"Keshtgarpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2005.09.002_bib1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/ajhp\/59.7.611","article-title":"Lung cancer: a review","volume":"59","author":"Cersosimo","year":"2002","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.lungcan.2005.09.002_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0169-5002(02)00308-2","article-title":"A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer","volume":"39","author":"Massarelli","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2005.09.002_bib3","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","article-title":"Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group","volume":"18","author":"Fossella","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2005.09.002_bib4","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2005.09.002_bib5","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2002.02.068","article-title":"Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer","volume":"20","author":"Scagliotti","year":"2002","journal-title":"J Clin Oncol"},{"doi-asserted-by":"crossref","unstructured":"Baselga J, Averbuch SD. ZD1839 (\u2018Iressa\u2019) as an anticancer agent. Drugs 2000;60(Suppl. 1):33\u201340; (discussion 41\u20132).","key":"10.1016\/j.lungcan.2005.09.002_bib6","DOI":"10.2165\/00003495-200060001-00004"},{"key":"10.1016\/j.lungcan.2005.09.002_bib7","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.lungcan.2005.09.002_bib8","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial)","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2005.09.002_bib9","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2004.08.158","article-title":"Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer","volume":"22","author":"Miller","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2005.09.002_bib10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/annonc\/mdh177","article-title":"Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients","volume":"15","author":"Haringhuizen","year":"2004","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.lungcan.2005.09.002_bib11","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1038\/sj.bjc.6601387","article-title":"Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer","volume":"89","author":"Gridelli","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lungcan.2005.09.002_bib12","first-page":"1873","article-title":"Gefitinib as salvage therapy in pretreated patients with advanced non-small cell lung cancer data from a compassionate use program","volume":"24","author":"Gridelli","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.lungcan.2005.09.002_bib13","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1158\/1078-0432.CCR-04-0189","article-title":"Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer","volume":"10","author":"Park","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2005.09.002_bib14","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/annonc\/mdh276","article-title":"Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial","volume":"15","author":"Ceresoli","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2005.09.002_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-2407-4-51","article-title":"Evaluation of safety and efficacy of gefitinib (\u2018iressa\u2019, zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme","volume":"4","author":"Mu","year":"2004","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2005.09.002_bib16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00520-004-0717-z","article-title":"Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa)","volume":"13","author":"Milton","year":"2005","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.lungcan.2005.09.002_bib17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.lungcan.2003.12.014","article-title":"Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839 \u201cIressa\u201d) on an expanded access study","volume":"44","author":"Janne","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2005.09.002_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.lungcan.2004.05.014","article-title":"Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity","volume":"47","author":"Chiu","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2005.09.002_bib19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000081005","article-title":"Brain metastasis responding to gefitinib alone","volume":"67","author":"Poon","year":"2004","journal-title":"Oncology"},{"key":"10.1016\/j.lungcan.2005.09.002_bib20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.lungcan.2004.04.036","article-title":"Effect of gefitinib (\u2018Iressa\u2019 ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer","volume":"46","author":"Hotta","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2005.09.002_bib21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2004.08.001","article-title":"Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1","volume":"22","author":"Giaccone","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2005.09.002_bib22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","article-title":"Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2","volume":"22","author":"Herbst","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2005.09.002_bib23","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1158\/1078-0432.CCR-04-1245","article-title":"High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan","volume":"10","author":"Huang","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2005.09.002_bib24","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2005.05.153","article-title":"Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial","volume":"23","author":"Cella","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2005.09.002_bib25","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/jnci\/djh217","article-title":"Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer","volume":"96","author":"Cappuzzo","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lungcan.2005.09.002_bib26","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.2003.01.039","article-title":"Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC","volume":"21","author":"Cappuzzo","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2005.09.002_bib27","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1158\/0008-5472.CAN-04-4235","article-title":"Somatic mutations of the HER2 kinase domain in lung adenocarcinomas","volume":"65","author":"Shigematsu","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2005.09.002_bib28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jnci\/dji055","article-title":"Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers","volume":"97","author":"Shigematsu","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lungcan.2005.09.002_bib29","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1200\/JCO.2005.08.043","article-title":"EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment","volume":"23","author":"Marchetti","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2005.09.002_bib30","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1078-0432.1167.11.3","article-title":"The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers","volume":"11","author":"Tokumo","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"11 Suppl. 12","key":"10.1016\/j.lungcan.2005.09.002_bib31","first-page":"23","article-title":"Can rash associated with HER1\/EGFR inhibition be used as a marker of treatment outcome?","volume":"17","author":"Perez-Soler","year":"2003","journal-title":"Oncology"},{"issue":"Suppl. 1","key":"10.1016\/j.lungcan.2005.09.002_bib32","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.3816\/CLC.2004.s.010","article-title":"Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer","volume":"6","author":"Perez-Soler","year":"2004","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.lungcan.2005.09.002_bib33","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2005.09.002_bib34","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/107327480301000506","article-title":"Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution","volume":"10","author":"Simon","year":"2003","journal-title":"Cancer Control"},{"issue":"Suppl. 1","key":"10.1016\/j.lungcan.2005.09.002_bib35","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.3816\/CLC.2004.s.014","article-title":"Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma","volume":"6","author":"Patel","year":"2004","journal-title":"Clin Lung Cancer"},{"issue":"12 Part 2","key":"10.1016\/j.lungcan.2005.09.002_bib36","doi-asserted-by":"crossref","first-page":"4238s","DOI":"10.1158\/1078-0432.CCR-040017","article-title":"The role of erlotinib (Tarceva OSI 774) in the treatment of non-small cell lung cancer","volume":"10","author":"Perez-Soler","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2005.09.002_bib37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2004.06.075","article-title":"Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck","volume":"22","author":"Soulieres","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2005.09.002_bib38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00001813-200502000-00011","article-title":"Treatment of non-small cell lung cancer with gefitinib (\u2018Iressa\u2019 ZD1839): the Greek experience with a compassionate-use program","volume":"16","author":"Razis","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.lungcan.2005.09.002_bib39","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/sj.bjc.6601923","article-title":"Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (\u2018Iressa\u2019 ZD1839) in non-small-cell lung cancer","volume":"91","author":"Parra","year":"2004","journal-title":"Br J Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.lungcan.2005.09.002_bib40","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1038\/sj.bjc.6601478","article-title":"Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib","volume":"89","author":"Katz","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lungcan.2005.09.002_bib41","doi-asserted-by":"crossref","first-page":"718","DOI":"10.2169\/internalmedicine.43.718","article-title":"Gefitinib as a first-line of therapy in non-small cell lung cancer with brain metastases","volume":"43","author":"Ishida","year":"2004","journal-title":"Intern Med"},{"doi-asserted-by":"crossref","unstructured":"Thatcher N, Chang A, Parikh P, Pemberton K, Archer V. Results of phase III placebo-controlled study (ISEL) of gefitinib (IRESSA) plus best supportive care (BSC) in patients with advanced non-small-cell lung cancer (NSCLC) who had received 1 or 2 prior chemotherapy regimens. In: Proceedings of the Supplement AACR: LB-6, 2005.","key":"10.1016\/j.lungcan.2005.09.002_bib42","DOI":"10.1016\/S0169-5002(05)80130-8"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500205005027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500205005027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T12:32:56Z","timestamp":1683289976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500205005027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S0169500205005027"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2005.09.002","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}